Clinical Rheumatology

, Volume 34, Issue 7, pp 1243–1248 | Cite as

Association of abnormal lipid spectrum with the disease activity of Takayasu arteritis

Original Article


Our study aimed to determine whether proatherogenic lipid profiles exist in patients with active Takayasu arteritis (TA) and assess the relationship between different lipid profiles and disease activity in TA. A total of 132 premenopausal female patients with TA and 100 sex-, age-, and body mass index-matched healthy controls were included in our study. The clinical data were collected in detail from all participants. Patients with active TA had significantly lower levels of apolipoprotein A1 (apoA1) (1.47 ± 0.30 vs. 1.99 ± 0.33 mmol/L, p < 0.001) and lower levels of high-density lipoprotein cholesterol (HDL-C) (1.23 ± 0.33 vs. 1.68 ± 0.38 mmol/L, p < 0.001) than patients with inactive TA. However, they had higher ratios of apolipoprotein B (apoB)/apoA1 (0.74 ± 0.27 vs. 0.48 ± 0.14, p < 0.001) compared with patients with inactive TA. Multiple linear regression analysis demonstrated that the apoB/apoA1 ratio was independently associated with TA activity (β = 0.38, p = 0.04). In addition, multivariate stepwise forward regression analysis showed that the apoB/apoA1 ratio was the major determinant for high-sensitivity C-reactive protein (β = 0.58, p = 0.002). Our findings indicate that patients with active TA had proatherogenic lipid profiles. In addition, the ratio of apoB to apoA1 could be used as a marker for monitoring and targeting patients with TA.


ApoB/ApoA1 ratio Atherosclerosis Disease activity Takayasu arteritis 


  1. 1.
    Subramanyan R, Joy J, Balakrishnan KG (1989) Natural history of aortoarteritis (Takayasu’s disease). Circulation 80:429–437PubMedCrossRefGoogle Scholar
  2. 2.
    Park KC, Kim JH, Yoon SS, Heo SH (2008) Takayasu’s disease presenting with atherothrombotic ischaemic stroke. Neurol Sci 29:363–366PubMedCrossRefGoogle Scholar
  3. 3.
    Seyahi E, Ugurlu S, Cumali R, Balci H, Seyahi N, Yurdakul S et al (2006) Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 65:1202–1207PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Numano F, Okawara M, Inomata H, Kobayashi Y (2000) Takayasu’s arteritis. Lancet 356:1023–1025PubMedCrossRefGoogle Scholar
  5. 5.
    Raninen RO, Kupari MM, Hekali PE (2002) Carotid and femoral artery stiffness in Takayasu’s arteritis. An ultrasound study. Sacnd J Rheumatol 31:85–88CrossRefGoogle Scholar
  6. 6.
    Park SH, Chung JW, Lee JW, Han MH, Park JH (2001) Carotid artery involvement in Takayasu’s arteritis: evaluation of the activity by ultrasonography. J Ultrasound Med 20:371–378PubMedGoogle Scholar
  7. 7.
    de Carvalho JF, Bonfá E, Bezerra MC, Pereira RM (2009) High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clin Rheumatol 28:801–805PubMedCrossRefGoogle Scholar
  8. 8.
    Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM et al (1990) The American College of Rheumatology 1990 criteria classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134PubMedCrossRefGoogle Scholar
  9. 9.
    Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54(Suppl):S155–S163PubMedCrossRefGoogle Scholar
  10. 10.
    Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M et al (1994) Takayasu arteritis. Ann Intern Med 120:919–929PubMedCrossRefGoogle Scholar
  11. 11.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) JAMA 285:2486–2497CrossRefGoogle Scholar
  12. 12.
    Tani S, Saito Y, Anazawa T, Kawamata H, Furuya S, Takahashi H et al (2011) Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study. Int Heart J 52:343–347PubMedCrossRefGoogle Scholar
  13. 13.
    Kim SW, Jee JH, Kim HJ, Jin SM, Suh S, Bae JC et al (2013) Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol 3:2678–2683CrossRefGoogle Scholar
  14. 14.
    Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J et al (2009) Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 30:710–717PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Mattsson N, Magnussen CG, Rönnemaa T, Mallat Z, Benessiano J, Jula A et al (2010) Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol 30:1861–1866PubMedCrossRefGoogle Scholar
  16. 16.
    Paradis ME, Badellino KO, Rader DJ, Deshaies Y, Couture P, Archer WR et al (2006) Endothelial lipase is associated with inflammation in humans. J Lipid Res 47:2808–2813PubMedCrossRefGoogle Scholar
  17. 17.
    de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfá E (2004) Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 50:3610–3615PubMedCrossRefGoogle Scholar
  18. 18.
    Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR et al (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:1169–1196PubMedCrossRefGoogle Scholar
  19. 19.
    Dullaart RP, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A (2010) Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta 1801:84–88PubMedCrossRefGoogle Scholar
  20. 20.
    Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533PubMedCrossRefGoogle Scholar
  21. 21.
    Sniderman AD (2005) Apolipoprotein B versus non-high-density lipoprotein cholesterol—and the winner is…. Circulation 112:3366–3367PubMedCrossRefGoogle Scholar
  22. 22.
    Faraj M, Messier L, Bastard JP, Tardif A, Godbout A, Prud’homme D et al (2006) Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 49:1637–1646PubMedCrossRefGoogle Scholar
  23. 23.
    Onat A, Can G, Hergenç G, Yazici M, Karabulut A, Albayrak S (2007) Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 31:1119–1125CrossRefGoogle Scholar
  24. 24.
    Seko Y (2007) Giant cell and Takayasu arteritis. Curr Opin Rheumatol 19:39–43PubMedCrossRefGoogle Scholar
  25. 25.
    Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD (2004) The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42:1355–1363PubMedCrossRefGoogle Scholar
  26. 26.
    Blum A, Shamburek R (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203:325–330PubMedCrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2014

Authors and Affiliations

  1. 1.State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations